GRK5 and cancer: The results indicated that 54/172 (31.40%, GRK5) and 53/172 (30.81%, ACTC1) of the cancer samples had low/absent staining (rated as low expression) and 118/172 (68.60%, GRK5) and 119/172 (69.19%, ACTC1) had moderate/strong staining (rated as high expression), while the IHC analysis of the 41 paratumor tissues indicated that 29/41 (70.73%, GRK5) and 32/41 (78.05%, ACTC1) of the paratumor samples had low/absent staining and 12/41 (29.27%, GRK5) and 9/41 (21.95%, ACTC1) had moderate/strong staining.